Results 31 to 40 of about 1,126 (138)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience

Hematology Reports, 2023
Prophylactic treatment with emicizumab has become an important and effective bleeding prevention for people with hemophilia A (PwHA). Perioperative management of PwHA using emicizumab prophylaxis is still challenging due to a lack of experience.
Karla Rener, Saša Anžej Doma, Martina Fink, Helena Podgornik, Irena Preložnik Zupan   +4 more
doaj   +1 more source

A Rare Case of Acquired Haemophilia A Following Sigmoid Adenocarcinoma: Case Report and Literature Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Acquired haemophilia A (AHA) is a rare complication of malignancy. We report a case of AHA secondary to colorectal cancer which presented as post‐operative bleeding, progressive activated partial thromboplastin time prolongation, precipitous factor VIII (FVIII) decline and inhibitor development.
Benjamin Reardon, Harini Haran, Jennifer Curnow   +2 more
wiley   +1 more source

Essentials of Laboratory Issues in the Patients with Emicizumab Therapy

, 2023
The recent development of emicizumab (Hemlibra, previously referred to as ACE910; Hoffman-La Roche) extends treatment options for hemophilia A patients, with and without anti-factor VIII (FVIII) inhibitors, and provides an alternative to FVIII ...
Sang Hyuk Park
core   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

TH Open, 2018
Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa and FX/FXa, a question may arise whether emicizumab competes with ...
Mariko Noguchi-Sasaki, Tetsuhiro Soeda, Atsunori Ueyama, Atsushi Muto, Michinori Hirata, Hidetomo Kitamura, Kaori Fujimoto-Ouchi, Yoshiki Kawabe, Keiji Nogami, Midori Shima, Takehisa Kitazawa   +10 more
doaj   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis

Research and Practice in Thrombosis and Haemostasis
Background: Recurrent joint bleeding in people with hemophilia A (PwHA) can cause hemophilic arthropathy, resulting in limited movement and chronic pain.
Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami   +11 more
doaj   +1 more source

Physical Activity and Sedentary Behaviour in Children With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Physical activity (PA) is vital in child development, while inactivity remains a leading contributor to global mortality. Therapeutic advances have enabled greater PA in boys with haemophilia (BwH), yet robust UK data on objectively measured PA and sedentary behaviour (SB) across severities are limited.
Melanie Bladen, Lucy Alderson, Eleanor Main, Mario Cortina‐Borja   +3 more
wiley   +1 more source

In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients

, 2022
BACKGROUND: Heparin management in hemophilia A (HA) patients with a factor VIII (FVIII) inhibitor can be challenging due to severe activated clotting time (ACT) prolongations. It is important to better understand the impact of emicizumab, a FVIII mimetic
Tanaka, Kenichi A, Henderson, Reney, Kiruphagaran Thangaraju, Upendra Katneni, Morita, Yoshihisa, Katneni, Upendra, Mazzeffi, Michael A, Erik Strauss, Buehler, Paul W, Yoshihisa Morita, Strauss, Erik, Michael A. Mazzeffi, Kenichi A. Tanaka, Paul W. Buehler, Thangaraju, Kiruphagaran, Reney Henderson   +15 more
core   +1 more source

Symptoms, Diagnosis, and Treatment for Women and Girls With Hemophilia: A Narrative Review

Haemophilia, EarlyView.
ABSTRACT Introduction Hemophilia is an X‐linked bleeding disorder previously thought to present only in men. This sentiment is rapidly changing as the information around women and girls’ experiences of bleeding symptoms has evolved, sparking intense discussion among researchers, clinicians, patients, and patient advocates regarding appropriate ...
Sam Hirniak, Carla Samuel, Faria Aditi, Haya Abu Ghazaleh, Dawn Rotellini, Menaka Pai, Andrea Edginton   +6 more
wiley   +1 more source